MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Lowers Holdings in Natera, Inc. (NASDAQ:NTRA)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lessened its position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 21.1% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 32,008 shares of the medical research company's stock after selling 8,550 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.'s holdings in Natera were worth $5,068,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the company. Principal Securities Inc. lifted its holdings in shares of Natera by 20.7% in the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock valued at $54,000 after buying an additional 59 shares during the period. Gladstone Institutional Advisory LLC lifted its holdings in shares of Natera by 1.7% in the 4th quarter. Gladstone Institutional Advisory LLC now owns 3,629 shares of the medical research company's stock valued at $574,000 after buying an additional 61 shares during the period. Silver Oak Securities Incorporated lifted its holdings in shares of Natera by 3.1% in the 4th quarter. Silver Oak Securities Incorporated now owns 2,963 shares of the medical research company's stock valued at $470,000 after buying an additional 89 shares during the period. Colonial Trust Co SC lifted its holdings in shares of Natera by 7.8% in the 4th quarter. Colonial Trust Co SC now owns 1,325 shares of the medical research company's stock valued at $210,000 after buying an additional 96 shares during the period. Finally, Blue Trust Inc. lifted its holdings in shares of Natera by 104.3% in the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock valued at $30,000 after buying an additional 97 shares during the period. Hedge funds and other institutional investors own 99.90% of the company's stock.

Natera Price Performance

Shares of Natera stock traded up $0.84 during mid-day trading on Friday, reaching $153.32. 1,085,198 shares of the stock traded hands, compared to its average volume of 1,392,841. The business has a 50-day moving average of $149.39 and a 200 day moving average of $157.72. Natera, Inc. has a fifty-two week low of $92.14 and a fifty-two week high of $183.00. The stock has a market capitalization of $20.94 billion, a PE ratio of -87.11 and a beta of 1.79. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33.

Natera (NASDAQ:NTRA - Get Free Report) last announced its earnings results on Thursday, May 8th. The medical research company reported ($0.50) EPS for the quarter, beating analysts' consensus estimates of ($0.59) by $0.09. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business had revenue of $501.83 million during the quarter, compared to analysts' expectations of $446.68 million. During the same quarter in the prior year, the firm earned ($0.56) earnings per share. The business's revenue was up 36.5% compared to the same quarter last year. On average, analysts predict that Natera, Inc. will post -1.49 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on NTRA. The Goldman Sachs Group boosted their price objective on Natera from $160.00 to $190.00 and gave the company a "buy" rating in a report on Tuesday, January 28th. UBS Group boosted their price objective on Natera from $211.00 to $218.00 and gave the company a "buy" rating in a report on Friday, May 9th. Morgan Stanley boosted their price objective on Natera from $176.00 to $185.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. Royal Bank of Canada initiated coverage on Natera in a report on Thursday, March 13th. They issued an "outperform" rating and a $251.00 price objective for the company. Finally, Piper Sandler upped their price target on Natera from $205.00 to $210.00 and gave the stock an "overweight" rating in a report on Thursday, May 15th. One research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $182.12.

Insider Buying and Selling at Natera

In other news, Director Gail Boxer Marcus sold 4,000 shares of the company's stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $151.61, for a total value of $606,440.00. Following the completion of the sale, the director now directly owns 9,704 shares in the company, valued at $1,471,223.44. This represents a 29.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Michael Burkes Brophy sold 2,562 shares of the company's stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $138.41, for a total value of $354,606.42. Following the completion of the sale, the chief financial officer now owns 75,557 shares of the company's stock, valued at $10,457,844.37. This trade represents a 3.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 152,436 shares of company stock valued at $22,019,079 over the last quarter. 7.60% of the stock is currently owned by insiders.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.